Compare HZO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | ALLO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 591.7M | 539.4M |
| IPO Year | 1998 | 2018 |
| Metric | HZO | ALLO |
|---|---|---|
| Price | $26.41 | $2.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $30.00 | $8.40 |
| AVG Volume (30 Days) | 434.3K | ★ 4.3M |
| Earning Date | 04-23-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | N/A |
| Revenue This Year | $3.02 | N/A |
| Revenue Next Year | $4.04 | $140,929.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.85 | $0.86 |
| 52 Week High | $32.00 | $2.80 |
| Indicator | HZO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 48.43 |
| Support Level | $24.44 | $1.04 |
| Resistance Level | $28.13 | $2.76 |
| Average True Range (ATR) | 1.37 | 0.21 |
| MACD | -0.14 | -0.06 |
| Stochastic Oscillator | 38.82 | 19.70 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.